Product Description
Mechanisms of Action: MGLUR5 Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Addex Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Gastroesophageal Reflux|Esophagitis, Peptic|Bile Reflux|Migraine Disorders|Migraine without Aura|Migraine with Aura
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2008-005105-18 | P2 |
Completed |
Bile Reflux|Gastroesophageal Reflux |
2012-12-11 |
|
ADX10059-206 | P2 |
Terminated |
Migraine Disorders |
2010-01-01 |
|
2008-005481-30 | P2 |
Terminated |
Migraine Disorders |
2009-12-14 |
|
ADX10059-205 | P2 |
Completed |
Esophagitis, Peptic|Gastroesophageal Reflux |
2009-12-01 |